15,000 Shares in United Therapeutics Corporation $UTHR Bought by Elmind Capital LP

Elmind Capital LP acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 15,000 shares of the biotechnology company’s stock, valued at approximately $8,127,450. United Therapeutics comprises about 0.0% of Elmind Capital LP’s portfolio, making the stock its 16th biggest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Torren Management LLC purchased a new position in United Therapeutics in the 4th quarter worth about $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. Fiduciary Financial Advisors purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at approximately $30,000. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares in the last quarter. Finally, Rakuten Securities Inc. grew its holdings in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent research reports. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $646.00.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total value of $4,914,160.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,827,875.04. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $23,631,280.08. The trade was a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 424,075 shares of company stock worth $227,336,485 over the last three months. 8.60% of the stock is currently owned by insiders.

United Therapeutics Trading Down 2.2%

NASDAQ:UTHR traded down $11.70 during trading hours on Friday, hitting $516.21. 176,234 shares of the stock traded hands, compared to its average volume of 488,078. The firm has a market cap of $22.14 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $303.08 and a fifty-two week high of $609.35. The firm has a 50 day moving average price of $530.89 and a 200 day moving average price of $538.86.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $6.41 EPS. Research analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.